Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomise...
Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial
About this item
Full title
Author / Creator
Straumann, A , Conus, S , Grzonka, P , Kita, H , Kephart, G , Bussmann, C , Beglinger, C , Smith, D A , Patel, J , Byrne, M and Simon, H-U
Publisher
England: BMJ Publishing Group Ltd and British Society of Gastroenterology
Journal title
Language
English
Formats
Publication information
Publisher
England: BMJ Publishing Group Ltd and British Society of Gastroenterology
Subjects
More information
Scope and Contents
Contents
Objective:Eosinophilic oesophagitis (EoO) is a clinicopathological condition defined by proton pump inhibitor-refractory oesophageal symptoms combined with oesophageal eosinophilia. The pharmacodynamic effect of mepolizumab (a humanised anti-interleukin-5 monoclonal antibody) in EoO was evaluated.Methods:Eleven adults with active EoO (>20 peak eosi...
Alternative Titles
Full title
Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_733562305
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_733562305
Other Identifiers
ISSN
0017-5749
E-ISSN
1468-3288
DOI
10.1136/gut.2009.178558
